Macular Degeneration Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922004|
|出版日期||內容資訊||英文 113 Pages
|全球黃斑部病變治療市場:成長，趨勢，及預測 Macular Degeneration Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 113 Pages||
The macular degeneration treatment market was projected to grow with a CAGR of nearly 7.4% during the forecast period. The major factors attributing to the growth of the macular degeneration treatment market are, rise in the incidence of retinal disorders, increasing the geriatric population in the majority of the developing nations. According to the data published in the European Society of Retina Specialists (EURETINA) an estimated number of 33.6 million persons over the age of 60 years in Europe are currently affected by AMD. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to the market growth. Furthermore, the increasing research and development investments, rising approvals for the new drugs of the treatment are other major factors for the market growth. However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints to the growth of the market.
As per the scope of the report, macular degeneration is a retinal disorder affecting older people. Early stages of the disease, (early and intermediate AMD) are generally asymptomatic, which gradually make progress to late stages of the disease, which can cause severe visual loss. This report is segmented by type, by stage of the disease, by route of administration and by geography.
Wet AMD accounts for the Majority of Share in the Market
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall macular degeneration treatment market, throughout the forecast period. The market growth is because of more awareness and a greater proportion of total income spent on healthcare compared to other economies. According to BrightFocus Foundation, in 2016, 11 million people in the United States have certain forms of age-related macular degeneration. This number is estimated to reach nearly 22 million by 2050. The growing patient pool and the increasing geriatric population who are more prone to retinal diseases are the two major factors driving the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth.
The macular degeneration treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch & Lomb Incorporated, IVERIC Bio, Neurotech Pharmaceuticals Inc., Alimera Sciences Inc., StemCells Inc., and Pfizer Inc.